Mito BioPharma
PrivateCompany Overview
Mito BioPharma is a biopharmaceutical company that develops small-molecule mitochondrial modulators to treat metabolic and liver-based diseases such as NASH, type 2 diabetes, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mito BioPharma Comparables
Compare Mito BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Equator Therapeutics | 86% | |
| MitoRx Therapeutics | 83% | |
| Abarceo Pharma | 80% | |
Mito BioPharma Funding Rounds
Historical fundraising activity
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
Monthly visitors grew 232% MoM, from 250 to 831.
- May 1, 2025
Monthly visitors increased 66% MoM.
Mito BioPharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mito BioPharma's valuation, stock price, and market status.